- Home
- RERE vs OLMA Comparison
RERE vs OLMA Comparison
Compare RERE & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RERE | OLMA |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 859.3M | 2.0B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RERE | OLMA |
|---|---|---|
| Price | $5.58 | $15.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $41.13 |
| AVG Volume (30 Days) | 864.7K | ★ 1.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.77 | N/A |
| Revenue Next Year | $25.01 | N/A |
| P/E Ratio | $34.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.00 | $2.86 |
| 52 Week High | $6.47 | $36.26 |
Technical Indicators
Market Signals| Indicator | RERE | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 47.44 | 21.53 |
| Support Level | $5.37 | $4.35 |
| Resistance Level | $5.61 | $27.38 |
| Average True Range (ATR) | 0.31 | 1.34 |
| MACD | -0.00 | -0.88 |
| Stochastic Oscillator | 31.10 | 1.02 |
Price Performance
Historical ComparisonAbout RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.